BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 16390400)

  • 1. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
    Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
    Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
    Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
    Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
    Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance.
    Bilgrami S; Aslanzadeh J; Feingold JM; Bona RD; Clive J; Dorsky D; Edwards RL; Tutschka PJ
    Bone Marrow Transplant; 1999 Jul; 24(1):69-73. PubMed ID: 10435738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
    Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
    Capria S; Gentile G; Capobianchi A; Cardarelli L; Gianfelici V; Trisolini SM; Foà R; Martino P; Meloni G
    J Med Virol; 2010 Jul; 82(7):1201-7. PubMed ID: 20513085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients.
    Chiaramonte S; Pellizzer G; Rassu M; Dissegna D; Bragantiini L; Zuccarotto D; La Greca G
    Clin Nephrol; 2000 Apr; 53(4):suppl 10-2. PubMed ID: 10809428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.
    Gentile G; Picardi A; Capobianchi A; Spagnoli A; Cudillo L; Dentamaro T; Tendas A; Cupelli L; Ciotti M; Volpi A; Amadori S; Martino P; de Fabritiis P
    BMC Infect Dis; 2006 Nov; 6():167. PubMed ID: 17118205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
    Yoon HS; Lee JH; Choi ES; Seo JJ; Moon HN; Kim MN; Im HJ
    Pediatr Transplant; 2009 Nov; 13(7):898-905. PubMed ID: 19032414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
    Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.